下気道治療薬の世界市場レポート 2025年

下気道治療薬の市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.2％で534億7,000万米ドルに成長します。予測期間の成長は、大気汚染レベルの上昇、高齢化、抗菌剤耐性、環境要因に起因すると考えられます。予測期間の主な動向には、精密医療アプローチ、技術革新、生物学的療法、呼吸器ケアにおける遠隔医療、個別化吸入デバイスなどが含まれます。

呼吸器疾患の発生が増加していることから、下気道治療薬市場は今後大幅に強化される見通しです。呼吸器疾患には、肺、気管支、気管、喉頭、咽頭、鼻腔などの呼吸器系に影響を及ぼすさまざまな病状が含まれます。下気道治療薬は、これらの疾患の早期発見と診断において極めて重要な役割を果たし、タイムリーな介入と管理を可能にします。この積極的なアプローチにより、疾患の進行を食い止め、感染性呼吸器疾患の蔓延を抑制し、合併症の可能性を軽減することができます。スイスに本部を置く市民団体NCDアライアンスが2022年9月に報告したデータによると、肺がんは世界のがん関連死亡の主な原因であり、年間220万人が新たに発症し、180万人が死亡すると予測されています。さらに、慢性呼吸器疾患は全世界で5億5,000万人の成人に影響を与え、420万人が死亡し、死亡者全体の7％を占めています。このように、呼吸器疾患の有病率の上昇は、下気道治療薬市場の成長を促進する大きな原動力として作用します。

喫煙率の上昇は、今後の下気道治療薬市場の成長を促進すると予測されています。喫煙とは、タバコやその他の物質を燃やした煙を吸ったり吐いたりすることです。下気道治療薬は、炎症を緩和し、症状を軽減し、病気の進行を遅らせ、気流と肺機能を改善し、増悪の頻度と重症度を低下させ、酸素濃度を高め、禁煙に成功する可能性を高めるために使用されます。例えば、2023年7月、スイスに本部を置く政府間機関である世界保健機関（WHO）の報告書によると、タバコの使用によって年間800万人以上が死亡し、その中には副流煙にさらされる非喫煙者も130万人含まれています。その結果、喫煙の蔓延が下気道治療薬市場の拡大に拍車をかけています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の下気道治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の下気道治療薬市場：成長率分析
• 世界の下気道治療薬市場の実績：規模と成長, 2019-2024
• 世界の下気道治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界の下気道治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の下気道治療薬市場：疾患タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 喘息
• 慢性閉塞性肺疾患
• 肺炎
• 気管支炎
• その他の病気
• 世界の下気道治療薬市場：薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗生物質
• 非ステロイド性抗炎症薬
• 咳止め薬
• 鼻づまり解消薬
• その他の薬物クラス
• 世界の下気道治療薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の下気道治療薬市場、タイプ別サブセグメンテーション：喘息、実績と予測, 2019-2024, 2024-2029F, 2034F
• アレルギー性喘息
• 非アレルギー性喘息
• 世界の下気道治療薬市場、タイプ別サブセグメンテーション：慢性閉塞性肺疾患（COPD）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 慢性気管支炎
• 肺気腫
• 世界の下気道治療薬市場、タイプ別サブセグメンテーション：肺炎、実績と予測, 2019-2024, 2024-2029F, 2034F
• 細菌性肺炎
• ウイルス性肺炎
• 世界の下気道治療薬市場、タイプ別サブセグメンテーション：結核、実績と予測, 2019-2024, 2024-2029F, 2034F
• 薬剤感受性結核
• 薬剤耐性結核
• 世界の下気道治療薬市場、タイプ別サブセグメンテーション：気管支炎、実績と予測, 2019-2024, 2024-2029F, 2034F
• 急性気管支炎
• 慢性気管支炎
• 世界の下気道治療薬市場、タイプ別サブセグメンテーション：その他の疾患、実績と予測, 2019-2024, 2024-2029F, 2034F
• 間質性肺疾患
• 嚢胞性線維症
• 肺高血圧症

第7章 地域別・国別分析

• 世界の下気道治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の下気道治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 下気道治療薬市場：競合情勢
• 下気道治療薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis AG
• Sanofi S.A.
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• GlaxoSmithKline plc.
• Eli Lilly and Co Ltd.
• Boehringer Ingelheim International GmbH
• Teva Pharmaceutical Industries Ltd.
• Regeneron Pharmaceuticals Inc.
• Vertex Pharmaceuticals Incorporated
• Grifols S.A.
• Menarini Group
• Chiesi Farmaceutici S.p.A.
• Cipla Limited
• Mundipharma International Limited

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 下気道治療薬市場2029：新たな機会を提供する国
• 下気道治療薬市場2029：新たな機会を提供するセグメント
• 下気道治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

The lower respiratory tract constitutes the segment of the respiratory system responsible for the exchange of gases, wherein oxygen is taken in, and carbon dioxide is expelled. Lower respiratory tract therapeutics is a specialized field within medical science and clinical practice that is dedicated to the diagnosis, treatment, and management of diseases and disorders affecting the lower respiratory tract. These therapeutic interventions aim to enhance the quality of life and overall health outcomes for individuals grappling with lower respiratory tract disorders.

The primary disease types addressed by lower respiratory tract therapeutics include asthma, chronic obstructive pulmonary disease (COPD), pneumonia, tuberculosis, bronchitis, and others. Asthma, for instance, is a chronic respiratory disorder characterized by inflammation of the airways, resulting in their narrowing and leading to frequent bouts of coughing, wheezing, chest tightness, and shortness of breath. Various drug classes are employed in lower respiratory tract therapeutics, including antibiotics, non-steroidal anti-inflammatory drugs (NSAIDs), cough suppressants, nasal decongestants, and others. These therapeutics are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies, providing individuals with access to the necessary medications for managing lower respiratory tract conditions.

The lower respiratory tract therapeutics market research report is one of a series of new reports from The Business Research Company that provides lower respiratory tract therapeutics market statistics, including lower respiratory tract therapeutics industry global market size, regional shares, competitors with lower respiratory tract therapeutics market share, detailed lower respiratory tract therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the lower respiratory tract therapeutics industry. This lower respiratory tract therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The lower respiratory tract therapeutics market size has grown strongly in recent years. It will grow from $36.03 billion in 2024 to $38.98 billion in 2025 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to antibiotic discoveries, vaccination programs, smoking cessation campaigns, advancements in inhalation therapy, healthcare infrastructure growth

The lower respiratory tract therapeutics market size is expected to see strong growth in the next few years. It will grow to $53.47 billion in 2029 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to rising air pollution levels, aging population, antimicrobial resistance, environmental factors. Major trends in the forecast period include precision medicine approaches, technological innovation, biologic therapies, telehealth in respiratory care, personalized inhalation devices.

The escalating occurrence of respiratory ailments is poised to significantly bolster the lower respiratory tract therapeutics market in the forthcoming period. Respiratory illnesses encompass a range of medical conditions impacting the respiratory system, including the lungs, bronchi, trachea, larynx, pharynx, and nasal passages. Lower respiratory tract therapeutics play a pivotal role in the early identification and diagnosis of these conditions, enabling timely intervention and management. This proactive approach aids in halting disease progression, controlling the spread of infectious respiratory diseases, and mitigating the likelihood of complications. As per data reported in September 2022 by the NCD Alliance, a civil society organization based in Switzerland, lung cancer stood as the leading cause of global cancer-related deaths, foreseeing an annual estimate of 2.2 million new cases and 1.8 million fatalities. Furthermore, chronic respiratory disorders impacted 550 million adults worldwide, resulting in 4.2 million deaths, constituting 7% of all mortalities. Thus, the escalating prevalence of respiratory diseases is set to act as a major impetus driving the growth of the lower respiratory tract therapeutics market.

The rising prevalence of smoking is anticipated to drive the growth of the lower respiratory tract therapeutics market in the future. Smoking involves inhaling and exhaling the smoke from burning tobacco or other substances. Lower respiratory tract therapeutics are used to alleviate inflammation, reduce symptoms, slow disease progression, improve airflow and lung function, decrease the frequency and severity of exacerbations, enhance oxygen levels, and increase the likelihood of successful smoking cessation. For instance, in July 2023, a report from the World Health Organization, a Switzerland-based intergovernmental organization, indicated that tobacco use kills over 8 million people annually, including 1.3 million non-smokers exposed to second-hand smoke. Consequently, the growing prevalence of smoking is fueling the expansion of the lower respiratory tract therapeutics market.

Product innovations are a key trend in the lower respiratory tract therapeutics market. Leading companies in this market are introducing new and innovative products to enhance their market position. For example, in November 2022, AstraZeneca PLC, a UK-based pharmaceutical and biotechnology company, and Sanofi S.A., a France-based pharmaceutical firm, launched Beyfortus to prevent lower respiratory tract disease in newborns and infants. This medicine has been approved by the European Union (E.U.) to prevent respiratory syncytial virus (RSV) and lower respiratory tract illnesses in newborns and infants during their first RSV season. Beyfortus is the first single-dose RSV passive immunization designed for the general newborn population, including healthy, full-term, premature babies, and those with special medical conditions.

Major players operating in the lower respiratory tract therapeutics market are concentrating on innovative offerings such as triple combination drugs tailored for COPD management to bolster their market revenues. This triple combination therapy for COPD comprises long-acting muscarinic antagonists (LAMA), long-acting beta-agonists (LABA), and inhaled corticosteroids (ICS) as the three primary inhaled medications. For instance, Lupin Limited, a pharmaceutical company based in India, introduced Vilfuro-G in November 2023. Vilfuro-G, available in a fixed dosage strength with once-daily dosing recommendations, is poised to significantly enhance the lives of COPD patients. This launch demonstrates Lupin's commitment to expanding its respiratory product line and providing healthcare professionals and patients with state-of-the-art treatment alternatives. Notably, Vilfuro-G stands as the only fixed-dose combination specifically formulated to combine glycopyrronium bromide, vilanterol, and fluticasone furoate for the long-term treatment and management of moderate to severe COPD.

In June 2022, Pfizer Inc., a prominent US-based pharmaceutical and biotechnology company, successfully acquired ReViral for an undisclosed amount. Through this acquisition, Pfizer seeks to broaden its portfolio of potential treatment options, with a particular focus on sisunatovir. Sisunatovir is an orally administered inhibitor specifically designed to prevent the respiratory syncytial virus (RSV) from attaching to the host cell's membrane. ReViral Ltd., the UK-based biopharmaceutical company that Pfizer acquired, is known for its dedication to developing novel antiviral therapeutics with a focus on targeting respiratory syncytial virus.

Major companies operating in the lower respiratory tract therapeutics market include Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc., Eli Lilly and Co Ltd., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Vertex Pharmaceuticals Incorporated, Grifols S.A., Menarini Group, Chiesi Farmaceutici S.p.A., Cipla Limited, Mundipharma International Limited, Orion Corporation, Sunovion Pharmaceuticals Inc., Innoviva Inc., Insmed Incorporated, Vectura Group plc, Theravance Biopharma Inc., Verona Pharma plc, Circassia Pharmaceuticals plc

North America was the largest region in the lower respiratory tract therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lower respiratory tract therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the lower respiratory tract therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The lower respiratory tract therapeutics market consists of sales of beta-lactam antibiotics, macrolides, and fluoroquinolones. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Lower Respiratory Tract Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on lower respiratory tract therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for lower respiratory tract therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The lower respiratory tract therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Disease Type: Asthma; Chronic Obstructive Pulmonary Disease; Pneumonia; Tuberculosis; Bronchitis; Other Diseases
• 2) By Drug Class: Antibiotics; Non-Steroidal Anti-Inflammatory Drug; Cough Suppressant; Nasal Decongestant; Other Drug Classes
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Asthma: Allergic Asthma; Non-allergic Asthma
• 2) By Chronic Obstructive Pulmonary Disease (COPD): Chronic Bronchitis; Emphysema
• 3) By Pneumonia: Bacterial Pneumonia; Viral Pneumonia
• 4) By Tuberculosis: Drug-sensitive Tuberculosis; Drug-resistant Tuberculosis
• 5) By Bronchitis: Acute Bronchitis; Chronic Bronchitis
• 6) By Other Diseases: Interstitial Lung Disease; Cystic Fibrosis; Pulmonary Hypertension
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Lower Respiratory Tract Therapeutics Market Characteristics

3. Lower Respiratory Tract Therapeutics Market Trends And Strategies

4. Lower Respiratory Tract Therapeutics Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Lower Respiratory Tract Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Lower Respiratory Tract Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Lower Respiratory Tract Therapeutics Market Growth Rate Analysis
• 5.4. Global Lower Respiratory Tract Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Lower Respiratory Tract Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Lower Respiratory Tract Therapeutics Total Addressable Market (TAM)

6. Lower Respiratory Tract Therapeutics Market Segmentation

• 6.1. Global Lower Respiratory Tract Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Asthma
• Chronic obstructive pulmonary disease
• Pneumonia
• Bronchitis
• Other Diseases
• 6.2. Global Lower Respiratory Tract Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antibiotics
• Non-Steroidal Anti-Inflammatory Drug
• Cough Suppressant
• Nasal Decongestant
• Other Drug Classes
• 6.3. Global Lower Respiratory Tract Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.4. Global Lower Respiratory Tract Therapeutics Market, Sub-Segmentation Of Asthma, By Tyoe, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Allergic Asthma
• Non-allergic Asthma
• 6.5. Global Lower Respiratory Tract Therapeutics Market, Sub-Segmentation Of Chronic Obstructive Pulmonary Disease (COPD), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chronic Bronchitis
• Emphysema
• 6.6. Global Lower Respiratory Tract Therapeutics Market, Sub-Segmentation Of Pneumonia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bacterial Pneumonia
• Viral Pneumonia
• 6.7. Global Lower Respiratory Tract Therapeutics Market, Sub-Segmentation Of Tuberculosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Drug-sensitive Tuberculosis
• Drug-resistant Tuberculosis
• 6.8. Global Lower Respiratory Tract Therapeutics Market, Sub-Segmentation Of Bronchitis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acute Bronchitis
• Chronic Bronchitis
• 6.9. Global Lower Respiratory Tract Therapeutics Market, Sub-Segmentation Of Other Diseases, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Interstitial Lung Disease
• Cystic Fibrosis
• Pulmonary Hypertension

7. Lower Respiratory Tract Therapeutics Market Regional And Country Analysis

• 7.1. Global Lower Respiratory Tract Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Lower Respiratory Tract Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Lower Respiratory Tract Therapeutics Market

• 8.1. Asia-Pacific Lower Respiratory Tract Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Lower Respiratory Tract Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Lower Respiratory Tract Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Lower Respiratory Tract Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Lower Respiratory Tract Therapeutics Market

• 9.1. China Lower Respiratory Tract Therapeutics Market Overview
• 9.2. China Lower Respiratory Tract Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Lower Respiratory Tract Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Lower Respiratory Tract Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Lower Respiratory Tract Therapeutics Market

• 10.1. India Lower Respiratory Tract Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Lower Respiratory Tract Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Lower Respiratory Tract Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Lower Respiratory Tract Therapeutics Market

• 11.1. Japan Lower Respiratory Tract Therapeutics Market Overview
• 11.2. Japan Lower Respiratory Tract Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Lower Respiratory Tract Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Lower Respiratory Tract Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Lower Respiratory Tract Therapeutics Market

• 12.1. Australia Lower Respiratory Tract Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Lower Respiratory Tract Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Lower Respiratory Tract Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Lower Respiratory Tract Therapeutics Market

• 13.1. Indonesia Lower Respiratory Tract Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Lower Respiratory Tract Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Lower Respiratory Tract Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Lower Respiratory Tract Therapeutics Market

• 14.1. South Korea Lower Respiratory Tract Therapeutics Market Overview
• 14.2. South Korea Lower Respiratory Tract Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Lower Respiratory Tract Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Lower Respiratory Tract Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Lower Respiratory Tract Therapeutics Market

• 15.1. Western Europe Lower Respiratory Tract Therapeutics Market Overview
• 15.2. Western Europe Lower Respiratory Tract Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Lower Respiratory Tract Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Lower Respiratory Tract Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Lower Respiratory Tract Therapeutics Market

• 16.1. UK Lower Respiratory Tract Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Lower Respiratory Tract Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Lower Respiratory Tract Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Lower Respiratory Tract Therapeutics Market

• 17.1. Germany Lower Respiratory Tract Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Lower Respiratory Tract Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Lower Respiratory Tract Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Lower Respiratory Tract Therapeutics Market

• 18.1. France Lower Respiratory Tract Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Lower Respiratory Tract Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Lower Respiratory Tract Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Lower Respiratory Tract Therapeutics Market

• 19.1. Italy Lower Respiratory Tract Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Lower Respiratory Tract Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Lower Respiratory Tract Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Lower Respiratory Tract Therapeutics Market

• 20.1. Spain Lower Respiratory Tract Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Lower Respiratory Tract Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Lower Respiratory Tract Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Lower Respiratory Tract Therapeutics Market

• 21.1. Eastern Europe Lower Respiratory Tract Therapeutics Market Overview
• 21.2. Eastern Europe Lower Respiratory Tract Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Lower Respiratory Tract Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Lower Respiratory Tract Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Lower Respiratory Tract Therapeutics Market

• 22.1. Russia Lower Respiratory Tract Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Lower Respiratory Tract Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Lower Respiratory Tract Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Lower Respiratory Tract Therapeutics Market

• 23.1. North America Lower Respiratory Tract Therapeutics Market Overview
• 23.2. North America Lower Respiratory Tract Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Lower Respiratory Tract Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Lower Respiratory Tract Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Lower Respiratory Tract Therapeutics Market

• 24.1. USA Lower Respiratory Tract Therapeutics Market Overview
• 24.2. USA Lower Respiratory Tract Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Lower Respiratory Tract Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Lower Respiratory Tract Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Lower Respiratory Tract Therapeutics Market

• 25.1. Canada Lower Respiratory Tract Therapeutics Market Overview
• 25.2. Canada Lower Respiratory Tract Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Lower Respiratory Tract Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Lower Respiratory Tract Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Lower Respiratory Tract Therapeutics Market

• 26.1. South America Lower Respiratory Tract Therapeutics Market Overview
• 26.2. South America Lower Respiratory Tract Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Lower Respiratory Tract Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Lower Respiratory Tract Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Lower Respiratory Tract Therapeutics Market

• 27.1. Brazil Lower Respiratory Tract Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Lower Respiratory Tract Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Lower Respiratory Tract Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Lower Respiratory Tract Therapeutics Market

• 28.1. Middle East Lower Respiratory Tract Therapeutics Market Overview
• 28.2. Middle East Lower Respiratory Tract Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Lower Respiratory Tract Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Lower Respiratory Tract Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Lower Respiratory Tract Therapeutics Market

• 29.1. Africa Lower Respiratory Tract Therapeutics Market Overview
• 29.2. Africa Lower Respiratory Tract Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Lower Respiratory Tract Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Lower Respiratory Tract Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Lower Respiratory Tract Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Lower Respiratory Tract Therapeutics Market Competitive Landscape
• 30.2. Lower Respiratory Tract Therapeutics Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Lower Respiratory Tract Therapeutics Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Sanofi S.A.
• 31.3. Bristol-Myers Squibb Company
• 31.4. AstraZeneca PLC
• 31.5. GlaxoSmithKline plc.
• 31.6. Eli Lilly and Co Ltd.
• 31.7. Boehringer Ingelheim International GmbH
• 31.8. Teva Pharmaceutical Industries Ltd.
• 31.9. Regeneron Pharmaceuticals Inc.
• 31.10. Vertex Pharmaceuticals Incorporated
• 31.11. Grifols S.A.
• 31.12. Menarini Group
• 31.13. Chiesi Farmaceutici S.p.A.
• 31.14. Cipla Limited
• 31.15. Mundipharma International Limited

32. Global Lower Respiratory Tract Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Lower Respiratory Tract Therapeutics Market

34. Recent Developments In The Lower Respiratory Tract Therapeutics Market

35. Lower Respiratory Tract Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Lower Respiratory Tract Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Lower Respiratory Tract Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Lower Respiratory Tract Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer